Evidence map›Paper›PMID 26187502›Full record

ReviewGut2015

Kyoto global consensus report on Helicobacter pylori gastritis.

Kentaro Sugano, Jan Tack, Ernst J Kuipers, David Y Graham, Emad M El-Omar, Soichiro Miura, Ken Haruma, Masahiro Asaka, Naomi Uemura, Peter Malfertheiner and 1 more

7 registry-linked trialsOpen access · bronzeAbstract readReviewConsensus Statement
In one paragraph

Review in Gut, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 783 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
783citing papers in PubMed, 15 pooled it
95.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03231332 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Long Term Effects of H.Pylori Eradication on Microbiome and Adverse Events

TypeinterventionalSponsorUniversity of LatviaRan2017 to 2025Enrolled900ConditionsHuman MicrobiomeArmsMicrobiome Diversity detection
NCT03592069 phase4completednot on this mapstarted 2018, after this paper: background citation

10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial

TypeinterventionalSponsorAlexandra Hospital, Athens, GreeceRan2018 to 2021Enrolled345ConditionsH.Pylori Infection, H.Pylori Gastrointestinal Disease, H. Pylori Associated Phlegmonous GastritisArms10 day concomitant regimen, 14 day hybrid regimen
NCT05469685 phase4completednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Vonoprazan- Amoxicillin Dual Therapy for Helicobacter Pylori Eradication : a Prospective, Multicenter, Randomized Controlled Trial

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2022 to 2023Enrolled914ConditionsHelicobacter Pylori InfectionArmsVonoprazan, Amoxicillin
NCT05649540 phase4completednot on this mapstarted 2023, after this paper: background citation

Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori:a Prospective, Multicenter, Open Label, Randomized Controlled Study:

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2023 to 2024Enrolled900ConditionsHelicobacter Pylori InfectionArmsVonoprazan, Amoxicillin
NCT05775120 unknown statusnot on this mapstarted 2022, after this paper: background citation

Epidemiology of Helicobacter Pylori Infection in Moscow

TypeobservationalSponsorMoscow Clinical Scientific CenterRan2022 to 2025Enrolled5,121ConditionsGastric Atrophy, Gastric Cancer, Helicobacter Pylori InfectionArmsOLGA and H.pylori culture
NCT07021729 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection

TypeinterventionalSponsorRehman Medical Institute - RMIRan2025 to 2026Enrolled156ConditionsHelicobacter Pylori InfectionArmsClarithromycin, Levofloxacin
NCT07179237 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Efficacy of Carminal on the Gastric Mucosa in Patients With Helicobacter Pylori Positive Gastritis

TypeinterventionalSponsorCatalysis SLRan2025 to 2026Enrolled80ConditionsH Pylori Gastritis, H Pylori Infection, H Pylori Eradication, Gastritis Associated With Helicobacter PyloriArmsCarminal Oral solution, Placebo
3 · Its place in the literature

Who cites it

783 citing papers in PubMed, 15 syntheses or guidelines pooled it, 1,740 citations in OpenAlex.

  1. [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026
    Guideline
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. To eradicate or not?Frontiers in medicine · 2026
    Pooled it
  7. Efficacy of probiotics pretreatment inAnnals of medicine · 2025
    Pooled it
  8. Pooled it
  9. First regional consensus on the management ofWorld journal of gastroenterology · 2025
    Guideline
  10. First-line Eradication of Helicobacter pylori Infection with High-Dose Amoxicillin and Vonoprazan: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Prevalence ofWorld journal of gastroenterology · 2024
    Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Amoxicillin high-dose dual therapy forWorld journal of gastroenterology · 2025
    Trial
  20. Trial

723 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Kentaro SuganoDepartment of Medicine, Jichi Medical University, Tochigi, Japan.
Jan TackTranslational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.
Ernst J KuipersDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherland.
David Y GrahamDepartment of Medicine, Michael E DeBakery VA Medical Center, Baylor College of Medicine, Houston, USA.
Emad M El-OmarDivision of Applied Medicine, Institute of Medical Sciences, Aberdeen University, Aberdeen, UK.
Soichiro MiuraNational Defense Medical College, Tokorozawa, Japan.
Ken HarumaDepartment of Gastroenterology, Kawasaki Medical School, Kurashiki, Japan.
Masahiro AsakaDepartment of Cancer Preventive Medicine, Hokkaido University, Sapporo, Japan.
Naomi UemuraKohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
Peter MalfertheinerDepartment of Gastroenterology, University of Magdeburg, Magdeburg, Germany.
faculty members of Kyoto Global Consensus Conference
Baylor College of Medicine · USErasmus MC · NLHokkaido University · JPJichi Medical University · JPKawasaki Medical School · JPKU Leuven · BENational Center for Global Health and Medicine · JPNational Defense Medical College · JPUniversity Hospital Magdeburg · DEUniversity of Aberdeen · GB

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

objectiveTo present results of the Kyoto Global Consensus Meeting, which was convened to develop global consensus on (1) classification of chronic gastritis and duodenitis, (2) clinical distinction of dyspepsia caused by Helicobacter pylori from functional dyspepsia, (3) appropriate diagnostic assessment of gastritis and (4) when, whom and how to treat H. pylori gastritis.

designTwenty-three clinical questions addressing the above-mentioned four domains were drafted for which expert panels were asked to formulate relevant statements. A Delphi method using an anonymous electronic system was adopted to develop the consensus, the level of which was predefined as ≥80%. Final modifications of clinical questions and consensus were achieved at the face-to-face meeting in Kyoto.

resultsAll 24 statements for 22 clinical questions after extensive modifications and omission of one clinical question were achieved with a consensus level of >80%. To better organise classification of gastritis and duodenitis based on aetiology, a new classification of gastritis and duodenitis is recommended for the 11th international classification. A new category of H. pylori-associated dyspepsia together with a diagnostic algorithm was proposed. The adoption of grading systems for gastric cancer risk stratification, and modern image-enhancing endoscopy for the diagnosis of gastritis, were recommended. Treatment to eradicate H. pylori infection before preneoplastic changes develop, if feasible, was recommended to minimise the risk of more serious complications of the infection.

conclusionsA global consensus for gastritis was developed for the first time, which will be the basis for an international classification system and for further research on the subject.

Indexed as

Practice Guidelines as TopicAnti-Bacterial AgentsDuodenitisGastritisGlobal HealthHelicobacter InfectionsHelicobacter pyloriHumansInternational Classification of DiseasesInternationalityJapanSurveys and QuestionnairesAnti-Bacterial AgentsFUNCTIONAL DYSPEPSIAGASTRIC CANCERGASTRITISHELICOBACTER PYLORI - GASTRITISHELICOBACTER PYLORI - TREATMENT

Identifiers

PMID26187502
PMCPMC4552923
OpenAlexW2183787411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.